Truist Financial Reiterates a Buy on Harmony Biosciences (HRMY)

​Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the Best Beaten Down Growth Stocks to Buy According to Analysts. On October 24, Danielle Brill from Truist Financial reiterated a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) without disclosing any price targets.

The rating follows the company’s pre-announcement of strong Q3 2025 WAKIX performance on October 23. The franchise generated around $239 million in revenue during the third quarter, reflecting 29% year-over-year growth. Management noted that these results were driven by a record rise in the average number of patients. The number of patients increased by 500 during the quarter to reach 8,100 average patients.

​In addition, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) also increased its revenue guidance for 2025 to a range of $845 million – $865 million versus the previous range of $820 million – $860 million.

​Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) develops and commercializes therapies for rare neurological diseases and other unmet medical needs.

While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.